In Vitro Diagnostics.
Ensure and Validate at Every Step of The Way.
Immunoassays provide a fast, simple, and cost-effective method of detection with high sensitivity and specificity. They exploit the properties of antibodies to identify disease biomarkers, drugs, and other analytes. Without a secure stream of validated mAbs, IVD developers and manufacturers risk nonspecific binding, batch variability, or loss of supply – leading to wasted time and resources or project abandonment.
Sequencing the protein of the antibody reagent in parallel to assessing its affinity and specificity facilitates the development of reliable kits and immunoreagents securing research and manufacturing reproducibility. Obtaining protein sequences also enable recombinant expression, yielding consistent batches with predictable biological activity. Next generation protein sequencing (NGPS) can also help avoid issues with mAbs stemming from cell line drift, gene loss, and gene mutations.
Services for In Vitro Diagnostic Developers.
We support IVD companies and reagent manufacturers in all stages of antibody selection, development, characterization, validation and production. Contact us to discover how we can help with your IVD application.
Antibody Sequencing & Discovery Services.
De Novo mAb Sequencing
Safeguard the sequence of high-demand immunoreagents for posterity, and/or IP, or to meet regulatory guidelines. Secure your antibody supply chain.
Explore REmAb
Fast ADA Assays
Custom anti-drug antibody (ADA) control reagents assess clinical safety and efficacy in biologics and biosimilars. ADAs derived from the circulating polyclonal antibodies (pAb) can be easily derived by polyclonal antibody sequencing.
Explore REpAb
Quality Control and Troubleshooting
Routinely certify immunoreagents by confirming the expected sequence for the highest quality with minimal troubleshooting.
Explore MATCHmAb
Binding Kinetics
Assess and validate antibody binding affinities, on-rates and off-rates, ensuring reagents are fit-for-purpose in your assay and adhering to quality by design principles.
Explore SPR
Epitope Mapping
Assess and validate antigenic epitopes of antibody products, ensuring the correct antibody targets and increased sensitivity of your assay through epitopic diversity.
Explore HDX-MS
Characterization Services
Our deep expertise working with antibodies, high throughput mass spectrometry and advanced software will give you critical insights in your antibody.
Explore Antibody Characterization Services
Application Publications.
Priming Agents Transiently Reduce the Clearance of Cell-Free DNA to Improve Liquid Biopsies
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Maximizing Liquid Biopsy Sensitivity through the Power of DNA-Binding Antibodies
In this webinar, you will learn: Non-Invasive Liquid Biopsies: Cell-free DNA as a key [...]
First Immunoassay for Measuring Isoaspartate in Human Serum Albumin
The ongoing pandemic has reinforced the need for in vitro diagnostics to globally surveille emerging pathogens and provide better medical care. In particular, immunoassays are favoured due to their affordability, ease, and speed. Nevertheless, the combination of rapidly evolving pathogens, and more complex diseases resulting from increasing life expectancy worldwide require more sensitive and specific immunoassays in the nick of time. To increase sensitivity, immunoassay development can benefit from exploiting industry-leading technologies such as de novo protein sequencing.
The Underlying Cause of Medical Diagnostic Invalidation
In-vitro diagnostics (IVDs) are one of the most commonly used tools to diagnose conditions and guide treatment decisions and are often considered the “silent champion” of healthcare. They work by detecting the absence or presence of particular markers or by measuring the concentration of analytes or specific substances.
“The protein sequence allowed us to control the antibody, affinity maturation, and do large production. Being able to produce 20mg of Ab is big advantage.”
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics